# The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas

**Authors:** Duygu Ayaz, Gülden Diniz, Ayşe Gül Pulular, Dudu Solakoğlu Kahraman, Umut Varol, Nuket Özkavruk Eliyatkın, Sevil Sayhan, Ali Kemal Kayapınar

PMC · DOI: 10.3390/curroncol32040190 · 2025-03-25

## TL;DR

This study explores how two proteins, NGAL and KIM-1, affect survival in gastric cancer patients and suggests their potential role in future treatments.

## Contribution

The study identifies NGAL and KIM-1 as potential prognostic markers and treatment targets in gastric carcinomas.

## Key findings

- KIM-1 and NGAL expression in tumor cells was associated with shorter survival times in gastric cancer patients.
- Simultaneous positivity for both proteins was more common among deceased patients.
- NGAL-positive inflammatory cells were present but not significantly linked to survival.

## Abstract

Background: The survival rate among stomach adenocarcinoma patients is exceedingly low. NGAL (neutrophil gelatinase-associated lipocalin) has pivotal roles in cell proliferation, immunity, and tumorigenesis. KIM-1 (Kidney Injury Molecule-1), also referred to as TIM-1 and HAVcr-1, is a transmembrane glycoprotein located in healthy immune cells and epithelial cells, and its upregulated form is generally found in several human cancers. Aim: The aim of this study was to investigate the prognostic significance of the expression of KIM-1 and NGAL in stomach cancers and identify NGAL-positive inflammatory cells in the tumor microenvironment. Materials and Methods: We immunohistochemically evaluated the expression of NGAL and KIM1 in 172 cases of stomach adenocarcinomas. Result: The mean age of the patients was 64.07 ± 12.35 years, and the mean and median follow-up period were 25.5 and 20.3 months, respectively. The expression rates of KIM-1 and NGAL in tumor cells were identical at 31.4% (n = 54). In 27 of these cases, both proteins were present. Among the deceased patients, the rate of simultaneous KIM-1 and NGAL positivity was relatively higher (p = 0.041). NGAL-positive inflammatory cells were observed in 13.4% of cases, with no significant correlation between these cells and survival times (p = 0.497). However, there was a negative correlation between survival times and KIM-1 (p = 0.037) and NGAL (p = 0.016) expressions in tumor cells. Conclusions: The present study has shown that KIM-1- and NGAL-positive tumor cells are influential in gastric tumorigenesis. Given the progress in anti-KIM-1 therapy, the presence of KIM-1 expression could contribute to the development of new treatment options for aggressive gastric cancer. However, these discoveries need to be validated in larger-scale studies.

## Linked entities

- **Genes:** LCN2 (lipocalin 2) [NCBI Gene 3934], HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762], ARHGEF5 (Rho guanine nucleotide exchange factor 5) [NCBI Gene 7984], HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762]
- **Proteins:** LCN2 (lipocalin 2), HAVCR1 (hepatitis A virus cellular receptor 1)
- **Diseases:** stomach adenocarcinoma (MONDO:0005036)

## Full-text entities

- **Genes:** LCN2 (lipocalin 2) [NCBI Gene 3934] {aka 24p3, MSFI, NGAL, p25}, HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762] {aka CD365, HAVCR, HAVCR-1, KIM-1, KIM1, TIM}
- **Diseases:** gastric tumorigenesis (MESH:D063646), Gastric Carcinomas (MESH:D013274), inflammatory (MESH:D007249), cancers (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12026346/full.md

---
Source: https://tomesphere.com/paper/PMC12026346